MedTrace Logo

Ruxolitinib to Combat COVID-19

NCT04354714 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-05-21

No results posted yet for this study

Summary

The investigators hypothesize that JAK 1/2 inhibition with ruxolitinib, an FDA approved treatment for intermediate or high-risk myelofibrosis, could have a similar effect in patients with severe COVID-19, quelling the immune-hyperactivation, allowing for clearance of the virus and reversal of the disease manifestations.

Conditions

Interventions

DRUG

Ruxolitinib

For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube

PROCEDURE

Peripheral blood draw

-Screening, Day 2, Day 4, Day 8, Day 15, and Day 29

Sponsors & Collaborators

  • Incyte Corporation

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • John DiPersio, M.D., Ph.D. · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2021-07-31
Completion
2021-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04354714 on ClinicalTrials.gov